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Abstract
Paraoxonase-1 (PON1) is an enzyme belonging to a
three-member gene family, each of which is highly
conserved in mammalian evolution. Whilst there is
consensus that the paraoxonase family members
have a general protective influence, their precise bio-
logical role has remained elusive. A toxicological role,
protecting from environmental poisoning by organo-
phosphate derivatives, drove much of the earlier work
on the enzymes. More recently, clinical interest has
focused on a protective role in vascular disease via a
hypothesised impact on lipoprotein lipid oxidation.
Recent confirmation that the primary activity of the
paraoxonases is that of a lactonase considerably
expands the potential sources of biological substrates
for the enzyme. Studies on such substrates may shed
further light on different mechanisms by which
paraoxonases beneficially influence atherosclerosis,
as well as defining possible roles in limiting bacterial
infection and in innate immunity.
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Introduction
Clinical interest in the serum enzyme paraoxonase-1
(PON1) has spanned over half a century without arriv-
ing at a consensus on its biological role. Neverthe-
less, the enzyme is something of a growth industry
with respect to the clinical attention it continues to at-
tract. A number of factors have contributed to the pre-
sent uncertainty about its role, in particular the
promiscuous range of substrates hydrolysed by the
enzyme. Very recent developments, which have iden-
tified the primary substrate group for PON1, should
significantly advance our understanding of its biolog-
ical function.
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This review looks at the past, present and future of
PON1 in terms of its emergence as a focus of some-
what diverse clinical interests.
The paraoxonase gene family
The paraoxonase gene family comprises three genes
(PON2, PON3, PON1) closely aligned in that order on
human chromosome 7 (1). There is substantial
(60–80%) sequence homology at the gene and protein
levels between the three PONs within a species, and
between corresponding PON members across spe-
cies. The family has arisen by gene duplication, with
PON2 being the ancestral gene, followed by the emer-
gence of PON3 then PON1.
Initial analyses indicated no homology with known
enzyme gene families, which could hint at the origins
and function of the PON family. Subsequent identifi-
cation of sequence similarities with lactonases, ini-
tially reported for a fungal lactonase (2), has led to
proposals of an evolutionary link between the two
types of enzyme. This hypothesis has been strength-
ened by recent reports concerning the substrate pref-
erences of PONs (see below).
The human PON genes are differentially expressed
(1, 3, 4). PON1 expression is largely confined to the
liver, as is PON3. Both enzymes can be released into
the circulation, although PON1 activity predominates
in man. Within serum, PON1 circulates tightly asso-
ciated with a subclass of lipoproteins, high-density
lipoprotein (HDL) (5). PON2 is more ubiquitously
expressed and does not appear to be released from
cells. It can be located in the cell membrane, with its
active site exposed to the external milieu. PON1
enjoys a similar orientation in the hepatocyte
membrane prior to its secretion and association with
HDL (6).
This overview predominantly focuses on PON1, for
which clinical interest has been most ardent in recent
years.
The past
The terminology ‘‘past’’ does not imply that the pre-
ceding focus of interest in PON1 is no longer or of
less clinical relevance. It should be taken to reflect
where attention was particularly centred in the contin-
uum of attempts to understand the biological role of
the enzyme. The period lasted from the discovery of
PON enzyme activity in 1946 to the early 1990s. Clin-
ical and biological interest was directed to the toxi-
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Figure 1 Basic structure of phosphoric acid triesters and
lactones.
cological associations of the enzyme, notably with
reference to environmental and military implications.
Substrate specificity and biological role
PON-type activity was first described in 1946 as the
capacity of tissues to hydrolyse organophosphate
(OP) derivatives (7). This esterase activity was charac-
terised in greater detail in mammalian sera (8), for
which two subclasses were defined: A-esterases,
encompassing PON, which are not inhibited by OP
compounds and are thus capable of neutralising
them; and B-esterases, exemplified by acetylcholin-
esterase, which are inactivated by such derivatives.
The highly toxic derivatives hydrolysed by the
enzyme are largely triesters of phosphoric acid (9)
(Figure 1). These include insecticides such as parathi-
on (metabolised to paraoxon, which is neutralised by
PON1) and diazinon (metabolised to diazoxon), as
well as nerve agents (sarin, soman). The enzyme is
also able to hydrolyse aromatic esters such as phe-
nylacetate and naphthyl acetate (10). Paraoxon and
phenylacetate are the two substrates most commonly
used to monitor activity of the enzyme, which can
give rise to a certain degree of confusion. Hydrolysis
of paraoxon (PON activity) gave rise to the name of
the enzyme; hydrolysis of phenylacetate is referred to
as arylesterase activity. There was considerable
debate as to whether the two activities resided in the
same or different proteins. The latter was, at one
point, taken to be the case (11), although this had
been contested (10). The issue was definitively
resolved by cloning of the gene (see below), whereby
the activities were shown to reside within the same
protein (12, 13).
A second area where confusion can arise relates to
activity polymorphism. It had been well established
that serum activity with paraoxon displayed a bimod-
al or trimodal distribution in populations, with sera
showing low, intermediate and high activity (10). Con-
versely, no such activity distribution was evident for
phenylacetate. The situation was also resolved by
cloning of the gene and the identification of a single
nucleotide polymorphism (SNP) at position 192. A
glutamine (Q) to arginine (R) exchange gives rise to
alleles with low (Q) and high (R) hydrolytic activity
towards paraoxon (12, 13). However, this is not a gen-
eral rule for the activity of the alleles towards sub-
strates. As indicated above, phenylacetate hydrolysis
does not show evident hydrolysis rate differences
between Q and R alleles, whilst other substrates wdia-
zoxin, sarin, (14)x show a higher hydrolytic rate with
the Q than the R allele.
During this period, little progress was made in iden-
tifying the physiological substrate of PON1 as a point-
er to its function. The xenobiotic nature of available
substrates gave few clues and was compounded by
the relaxed substrate specificity and inconsistent
effects of the 192 polymorphism on activities of avail-
able substrates. An early suggestion that there may
be a link to carboxylesterases (15) was scotched by
cloning of the PON1 gene, which showed no homol-
ogy with such enzymes.
Clinical interest
Clinical interest in PON1 during this period was driven
by its potential to neutralise environmental poisons
that block acetylcholinesterase. The toxic effects
of these compounds, arising from the inability of
inactivated acetylcholinesterase to eliminate acetyl-
choline, cause over-stimulation of nicotinic and mus-
carinic receptors in the central and peripheral nervous
systems, leading to the cholinergic syndrome (16).
Organophosphate poisoning has also been associat-
ed with delayed polyneuropathy, which involves inhi-
bition of a different central nervous system esterase
(17).
The short resume´ above implies that PON1 activity
is a determinant of susceptibility to OP poisoning.
Several studies supported this hypothesis. Animal
sensitivity to OPs correlates with levels of serum
PON1. Thus, birds, which are deficient in PON1, are
more susceptible to such poisons than mammals (18).
Conversely, rabbits have higher levels of PON activity
than rats and are more resistant than rats to OP poi-
soning (9). Injection of rats (19) and mice (20) with
partially purified PON increased their resistance to
OPs.
Resume´
The period until the early 1990s was dominated and
driven by the clinical potential of the enzyme to limit
OP poisoning, whether of an agricultural or military
nature. Contemporary data largely support this poten-
tial, and it was subsequently confirmed by later use
of transgenic animals (see below). Very little progress
was made in identifying physiological substrates and
defining the biological role of PON1. The consensus
was for a generally protective role with wide sub-
strate specificity.
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Table 1 Oxidised lipids postulated as substrates for
paraoxonase.
Lipid Reference
Cholesterol linoleate hydroperoxide (23)
Oxidised 1-palmitoyl-2-arachidonoyl-sn- (24)
glycero-3-phosphorylcholine (Ox-PAPC)
Oxidised linoleic acid (25)
The present
This period began in the early 1990s with two events
that radically changed clinical considerations about
PON and opened new avenues of research. The first
event was the hypothesis advanced by Mackness and
colleagues that PON1 may be able to prevent or limit
oxidation of low-density lipoprotein (LDL) lipids (21).
As the oxidative modification hypothesis (22) is a cen-
tral tenet of the relationship between LDL and athero-
sclerosis, the proposal thrust PON into the clinical
arena that is the principal cause of mortality and mor-
bidity in developed countries. The second event was
the cloning of the PON1 gene (12, 13), opening the
possibility of more sophisticated structure-function
studies, analysis of the enzyme active site, availability
of highly pure protein, and the development of animal
models. Clinical emphasis gradually shifted to the
involvement of PON in vascular disease, without los-
ing sight of its toxicological links.
Substrate specificity and biological role
Oxidation of LDL is the principal modification of this
lipoprotein species that renders it atherogenic and
capable of promoting atherosclerotic disease. The
hypothesised ability of PON to prevent or limit oxi-
dation prompted attempts to identify potential sub-
strates in the form of oxidised lipids. Several
candidates have been proposed, as indicated in Table
1. These arose essentially from single publications,
with no confirmation or further examination in sub-
sequent studies. This reflects in part the difficulties
and technical requirements needed to identify and
analyse such oxidised lipids. No consensus substrate
emerges from the list, although PON1 may be expect-
ed to have broad substrate specificity in this respect.
Another feature of this short list is the presence of
PON products, notably lysophospholipids, that are
biologically active, with both physiological and patho-
physiological effects (26). In this respect, the well-
established association of serum PON1 with HDL may
be of importance. HDLs carry a number of compo-
nents that protect against oxidative stress (27). A syn-
ergistic interaction between the components within
HDL may be necessary to counter the variety of lipid
products that can be generated by lipoprotein oxida-
tion, as proposed by Ahmed et al. (28).
The difficulties in identifying and analysing individ-
ual lipid oxidation products as potential PON1 sub-
strates should be underlined. The type of oxidation
process used and the length of exposure to oxidation
can modify the cocktail of oxidation end-products
(29). The oxidation products are not stable and, as
well as promoting further oxidation, degrade into
other products. This necessitates a certain degree of
specialisation and expertise in order to analyse such
molecules.
Thus, for a number of reasons, there has been little
progress in identifying oxidised lipids as substrates
for PON. In their absence, the bulk argument sup-
porting oxidised lipids as substrates for PON, and
indeed a role for the enzyme in suppressing lipopro-
tein oxidation, comes from more general measures of
lipid oxidation. The degree of lipid oxidation can be
quantified in terms of lipoperoxides, thiobarbituric
acid-reactive substances (TBARS) and conjugated
dienes (30). A number of studies carried out by a vari-
ety of independent groups show an inverse relation-
ship between the level of oxidised lipid products and
PON1 activity in vitro (23, 25, 31–33). Some studies
have also shown an inverse relationship between the
two parameters in vivo (34, 35). Furthermore, PON1-
deficient HDL from PON1 knockout mice was unable
to prevent oxidation of LDL, but the activity could be
restored by adding purified PON1 (36). The conse-
quences of modulating the PON1 complement of HDL,
and thus lipoprotein oxidation, have been linked to
the pathological characteristics of oxidised lipopro-
teins. HDL lacking PON1 is unable to prevent LDL
acquiring pro-atherogenic characteristics, notably
stimulation of monocyte migration and up-regulation
of monocyte chemotactic protein-1 (37, 38). Indeed,
loss of PON1 can induce an important change in HDL
as it veers from an anti-inflammatory to a pro-inflam-
matory complex (37), which fundamentally alters its
association with the atherosclerotic process.
In the continued absence of a defined physiological
substrate for PON1, paraoxon (PON activity) and phe-
nylacetate (arylesterase activity) remain the principal
means of monitoring enzyme activity. The question
thus arises as to what extent they mirror the anti-oxi-
dant activity of the enzyme. A number of studies have
reported positive correlations between activity with
these substrates and the anti-oxidant activity of PON1
(23, 25, 33). Others have shown a certain divergence
of the two activities (39, 40). Recent studies appear to
have clarified the issue. Using recombinant PON with
different mutations of the region encompassing the
active site, it was shown that arylesterase activity best
reflected the anti-oxidant function, even though it was
not directly responsible for it (41). In contrast,
paraoxon hydrolysis was a relatively poor substitute
for the anti-oxidant activity. This suggests that phe-
nylacetate hydrolysis can be used as a surrogate for
the anti-oxidant capacity, at least until a viable, widely
applicable assay becomes available for lactonase
activity (see below).
Clinical interest
The last 15 years have seen the possible protective
role of PON1 against atherosclerotic disease domi-
nate clinical interest in the enzyme for several con-
vergent reasons. As mentioned previously, LDL
oxidation has been one of the principal driving forces
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of atherosclerosis research. Equally important, the
tight association of PON1 with HDL locates it within
the lipoprotein complex that exerts a powerful, neg-
ative influence on the risk of vascular disease. Finally,
HDL has become a major therapeutic target for mod-
ulating the risk of vascular disease.
The strongest evidence for a protective role of
PON1 in cardiovascular disease comes from animal
studies. PON1 knockout mice show a significant
increase in the extent of atherosclerotic lesion devel-
opment (36), even in transgenic models (apoE:PON1
double knockout) in which the prevalence of athero-
sclerosis is equivalent to that observed in man (42).
Conversely, mice over-expressing PON1 are better
protected against lesion development (43). Confir-
mation of these conclusions has been recently fur-
nished in independent models. Kupfer (macrophage)
cell expression of PON1 significantly reduced lesion
formation in cholesterol-fed mice (44). The develop-
ment of atherosclerosis was also retarded in a mouse
model of the metabolic syndrome in which PON1 was
over-expressed (35). As with the earlier studies, the
PON1-mediated anti-oxidant activity of HDL was a
negative correlate of lesion formation.
As regards data from studies of human popula-
tions, these are consistent with a role for PON1 in vas-
cular disease, without providing unambiguous proof.
One prospective study has shown that reduced serum
PON1 activity was an independent predictor of coro-
nary disease (45). It was, however, based on
paraoxon hydrolysis and may require re-appraisal in
light of suggestions that such activity is not a reliable
surrogate for PON anti-oxidant activity (41). A wide
range of other studies has shown significantly lower
serum PON activity in patients with confirmed vas-
cular disease or in high-risk populations. These
include patients with coronary disease (46–48), dia-
betes (49–52), familial hypercholesterolaemia (53, 54),
the metabolic syndrome (55, 56), and smokers (52, 57,
58). In the context of some uncertainty about the val-
ue of enzyme activities as surrogates for anti-oxidant
function, analysis of serum PON peptide mass would
seem an appropriate alternative. It has occasionally
been analysed and shown to be reduced in high-risk
patients (47, 48).
PON1 activity is itself sensitive to the oxidative
stress status, which can lead to enzyme inactivation
(59). This may be a contributory factor to lower serum
PON1 in the clinical states outlined above, as all are
associated with increased oxidative stress. Converse-
ly, factors that diminish oxidation appear to improve
serum levels of the enzyme. Thus, positive dietary
effects on serum PON1 activity have been reported
with vitamin intake (60) and pomegranate juice
consumption (linked to its anti-oxidant content) (61).
Postprandial hypertriglyceridaemia was found to tran-
siently modulate serum PON1 activity and concentra-
tion (62), which may reflect the influence of the
triglyceride-rich lipoproteins on PON1 metabolism
(63).
Serum activity of the enzyme may also be amena-
ble to pharmacological manipulation. Statins, the
drug class most widely used to lower serum LDL, are
associated with improved serum concentrations and
activities of PON1 (64). A molecular basis for this
effect has been described (64, 65), suggesting that it
is not merely a side effect of reductions in LDL and
possible removal of oxidised lipids (which can inhibit
enzyme activity).
The toxicological role of PON continues to attract
attention, reflecting growing public concern with envi-
ronmental impacts on health. It was suggested that
children may be more susceptible to environmental
poisons owing to lower overall metabolic activity and
perhaps reduced expression of PON activity (66, 67).
Other clinical consequences of OP poisoning and
modified cholinergic function were also proposed,
including an impact on Parkinson’s disease (68) and
anxiety (69). These and similar studies require further
investigation, but they reflect the fact that the clinical
consequences of OP poisoning are potentially very
extensive (70). The advent of transgenic mice that
over- and under-express PON1 provided more solid
support for the hypothesis mentioned above on OP
sensitivity. PON1 knockout mice were more sensitive
to OP poisoning, where the Q and R 192 alleles dif-
fered in their protective effects (20). The higher the
hydrolytic activity of the allele, the greater is its pro-
tective effect, underlining the metabolic importance of
high hydrolytic capacity. Interestingly, PON1 knockout
mice showed little change in susceptibility to
paraoxon poisoning compared to wild-type mice.
Conversely, there were important differences in sus-
ceptibility to diazoxon. The explanation appears to lie
with the far greater hydrolytic rate of PON1 towards
diazoxon than paraoxon, even though the enzyme
neutralises paraoxon.
Resume´
There are persuasive arguments from animal studies
to support the hypothesis of a role for PON1 in ath-
erosclerotic disease. Data from human studies are
largely consistent with the hypothesis. In vitro studies
show a negative correlation between PON1 activity/
concentration and lipoprotein oxidation, although not
consistently, whilst in vivo a modulated capacity to
limit lipoprotein oxidation is a strong correlate of
altered serum PON1 levels. Several putative oxidised
lipids have been advanced as substrates for PON1,
but the absence of a consensus substrate remains a
limitation of the hypothesised role of the enzyme in
protecting lipids from oxidation.
The future
Studies over the last few years have provided firm
support for the contention that the basic enzyme
activity of PON1 is that of a lactonase, thus identifying
the principle substrate group as lactones and their
derivatives. This should largely condition the future
direction of research concerning the PON family func-
tion. It opens new perspectives for the enzyme, which
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Table 2 Lactone substrates for paraoxonase.
Substrate group Substrate
Oxidised lipid derivatives 5-hydroxy-eicosatetraenoic acid 1,5-lactone (5-HETEL)
4-hydroxy-docosahexaenoic acid (4-HDoHE)
Drug metabolism Simvastatin, lovastatin
Spironolactone
Prulifloxacin
Glucocorticoid g-lactones
Amino acid derivatives Homocysteine thiolactone
Bacterial signalling molecules Homoserine lactones
complement previous considerations of its biological
role and clinical relevance.
Substrate specificity and biological role
Sequence similarities revealed by genetic analyses
gave the first indications of links between the PON
family and lactonases (2). It was followed by
publications demonstrating that PON1 was capable of
hydrolysing lactone-based substrates (71, 72).
Detailed analyses by Khersonsky and Tawfik (73) and
Dragonov et al. (74) confirmed and affirmed lactonase
activity of the different PON family members. Both
groups analysed a wide selection of substrates rep-
resenting different hydrolytic activities, and conclud-
ed that lactonase (Figure 1B) was the principal
ancestral enzyme activity. In this context, the more
limited range of substrates hydrolysed by PON2,
which focuses on lactones, may reflect the core activ-
ity of the PON family, given that PON2 is the ancestral
gene, whilst PON1 and PON3 enzymes would have
evolved a wider range of substrate specificities (74).
The designation of lactones as the principal sub-
strates for PON opens a fascinating diversity of poten-
tial physiological substrates. These are outlined in
Table 2. The list is restricted at present to those mol-
ecules that have already been shown to be substrates
for PON1.
Clinical interest
The potential clinical relevance of lactonase activity
of PON enzymes is summarised in Table 2. Four areas
appear of notable interest. Links with vascular disease
via lipid oxidation still figure prominently via 5-
hydroxy-eicosatetraenoic acid 1,5-lactone (5-HETEL)
and 4-hydroxy-docosahexaenoic acid (4-HDoHE),
which are derivatives of the oxidised fatty acids ara-
chidonic and docosahexaenoic acid, respectively.
These, and other structurally related derivatives, nota-
bly lipoxins (75), can have potent biological activities,
particularly implicating the inflammatory response.
The latter is also of particular relevance to atheroscle-
rosis, which is now considered to be a chronic inflam-
matory disease (76). Identification of such substrates
that are metabolised by PON would strengthen the
role of PON as a modulator of the inflammatory
response. The latter is already implicit in the ability of
PON to limit lipoprotein oxidation, as oxidised lipids
provoke a powerful inflammatory reaction (77).
Links to vascular disease are also inherent to the
homocysteine thiolactonase activity of human sera
first reported by Jakubowski (72), who showed that it
resided within HDL and specifically PON1. Homocys-
teine is a strong independent risk factor for athero-
sclerosis (78). It can induce chemical modification of
peptides, a process in which homocysteine thiolac-
tone has been implicated (79). Such modifications can
alter peptide function, as well as rendering the pep-
tide immunogenic and susceptible to homocysteine-
induced oxidative stress (80). Thiolactonase activity
thus offers a protective mechanism against peptide
modifications that could promote atherogenic chang-
es in lipoproteins, amongst other blood components.
Homoserine lactones (HSLs) are an important fam-
ily of signalling factors in bacterial biology. They pro-
vide a communications network between bacteria,
termed quorum sensing, that allows coordinated reg-
ulation of gene expression to achieve a number of
objectives (81). It facilitates, for example, bacterial
infection and colonisation. The ability to neutralise
these signalling factors would thus represent a pro-
tective mechanism against bacterial infection. Recent
studies have clearly established that the PON family
can hydrolyse and neutralise HSLs (82, 83). In this
respect, PON2 appears to be more active than PON1
(74), perhaps reflecting the ancestral function of PON.
Incidentally, the cell membrane location of PON2
would be especially suitable for resisting bacterial
colonisation of tissue surfaces. Of particular interest
is the suggestion that the ability to inactivate HSLs
may be a feature of the innate immune system (82),
implying that the PON family may have an important
evolutionary role. On a speculative level, such activity
may also link PON1 to atherosclerosis, as bacterial
infection has been proposed as an independent risk
factor for vascular disease (84).
Finally, the lactonase activity of PON1 provides the
basis for a role in drug metabolism. The enzyme has
been shown to inactivate lactone derivatives of glu-
cocorticoids (85). This has been exploited to limit
unwanted side-effects of such drugs during topical
application by neutralising any drug diffusing outside
the area under treatment. The converse use of PON1
to activate prodrugs has also been exploited. This is
the case for the antibiotic prulifloxacin, which is given
in an inactive form and activated by serum PON1 (86).
The statin drugs lovastatin and simvastatin are also
activated by PON1 (87). This has pharmacogenetic
implications for patients treated with such drugs,
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although, to date, there are no indications of any
interaction between the enzyme and these drugs that
has influenced their use in patients.
Resume´
The identification of lactonase activity as the principal
function of the PON family has widened the number
of potential substrates and, thus, the clinical rele-
vance of the enzymes. Several biologically relevant
lactone substrates for PON1 have already been iden-
tified. These and other substrates need to be further
investigated and their true clinical impact defined.
The latter point should become a focus of attention
for PON1 research in the next decade. An association
with vascular disease still remains a strong candidate
for the clinical impact of the enzyme, which accords
with available data. This relationship would be
strengthened if stronger ties with the inflammatory
response were also revealed. Finally, the ability to
modulate bacterial virulence offers one appealing
explanation for the evolutionary stability of the PON
gene family, as it is likely to reflect a primitive but
continuing protective function. Furthermore, it opens
an avenue of research for a role of the PON proteins
in innate immunity.
Conclusions
Whilst identification of a precise biological role for the
PON family remains a primary objective, their desig-
nation as lactonases reinforces early indications of a
general and widespread protective function. In this
context, identification of a single, or a narrow range
of PON substrates may be too blinkered a view of
their function. Vascular disease has been the partic-
ular focus of the protective role in recent years, but
this could be extended to other areas of clinical inter-
est in the future. It will be particularly interesting to
examine if the association of PON1 with HDL repre-
sents adaptation of a previously static protective func-
tion to one of greater mobility and versatility.
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